Last week, I looked at a retrospective study of metastasis-directed therapy (MDT) at the Mayo Clinic among oligorecurrent patients (see this link). … READ MORE …
Filed under: Management, Treatment | Tagged: lymph, metastasis, node, oligorecurrent, radiation, salvage, therapy | 4 Comments »
A report this week in Urologic Oncology has confirmed the importance of PSA doubling times in understanding risk for prostate cancer progression among men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: castration-resistant, doubling, mCRPC, metastasis, nmCRPC, non-metastatic, PSA, survival | 1 Comment »
A newly published commentary on the CancerNetwork web site is entitled, “Radical prostatectomy as primary treatment for prostate cancer leads to better survival.” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: castration-resistant, CRPC, metastasis, outcome, radiation, surgery | 1 Comment »
A new paper in Clinical Genitourinary Cancer has provided us with some more detailed information about risk for metastasis in men with recurrent prostate cancer after first-line surgery. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: doubling, Gleason, metastasis, PSA, risk, score, time | 14 Comments »
New data from the ongoing STAMPEDE trial in the UK and Switzerland has now confirmed that ablative radiation of the prostate itself (debulking of the primary tumor) improves overall survival (OS) in men newly diagnosed with metastatic prostate cancer who have a low metastatic disease burden but not in those with higher burden of disease. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, debulking, deprivation, docetaxel, metastasis, primary, radiation, therapy, tumor | 7 Comments »
One of the more exciting new developments in radiopharmaceuticals for metastatic prostate cancer has been the development of alpha-particle emitters attached to PSMA ligands. We previously reported this update. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Ac-225-PSMA-617, castration-resistant, metastasis | 9 Comments »
There is an interesting editorial commentary by Dr. Daniel George that was published just over a week ago on the UroToday web site. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: metastasis, metastatic, non-metastatic | 16 Comments »
Some 35+ years ago, a guy called Barry Marshall and his colleague Robin Warren discovered that changes to the levels of certain bacteria in the gut led to development of ulcers … and changed everything about the way ulcers are treated. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: bacteria, gut, metastasis, research | 3 Comments »
A company based on Northern Ireland called Almac Diagnostics has been working on the development of a 70-gene genetic assay (which they refer to as their Prostate Cancer Metastatic Assay) capable of projecting probability of metastasis-free survival in men treated for prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: metastasis, prognosis, recurrence | 6 Comments »
A newly published article in the Journal of Clinical Oncology suggests that the Decipher test may be able to predict risk for metastatic prostate at 10 years post-surgery. However, … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Decipher, genomic, metastasis, post-surgery, prognosis, testing | Leave a comment »
One of the abstracts to be presented at ASCO this year gives us some insight into risk for and time to death among men with non-metastatic but castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, death, metastasis, nmCRPC, nonmetastatic, risk, time | 20 Comments »
According to new data reported at the annual meeting of the European Association of Urology in London, active surveillance of men diagnosed with low-risk prostate cancer was not associated with an elevated risk for metastatic disease at 15 years of follow-up. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, follow-up, metastasis, outcome, surveillance, survival | 8 Comments »
In a recent opinion piece in the Journal of Clinical Oncology, Dr. Anthony D’Amico (a prostate cancer specialist for whom we have great respect) has again aired his concerns about risk for progression to metastatic disease among men on active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, education, information, metastasis, risk, surveillance | 2 Comments »
The idea that one could stop the initiation of prostate cancer metastasis before it even starts is fundamental to the idea that we might be able to eliminate prostate cancer as a cause of death. And it’s as true for prostate cancer as it is for nearly every other form of cancer. The problem is that we don’t yet know why prostate cancer metastasizes … and many suspect there may be more than one reason. … READ MORE …
Filed under: Drugs in development | Tagged: biosynthetic, metastasis, miRNA, mitochondrial, RNA | 2 Comments »
Strictly speaking, JAMA Oncology actually ended the old year (in its issue on December 29, 2016), rather than beginning the new one, with two articles, a letter to the editor, and an editorial that deal with two of the more controversial issues that affect the way we think about the management of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: androgen, controversy, deprivation, IADT, intermitten, metastasis, risk, screening | 2 Comments »
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
THE "NEW" PROSTATE CANCER INFOLINK